Unpublished Study Pegs Cost Of New Drug At $231 Million

BOSTON - An unpublished study that examines the cost of bringing a new drug to market has revived debate over whether data should be released to the public prior to peer review. The study, which cites a figure that is nearly twice as high as previous estimates, is already being used in ongoing discussions over federal policies on drug pricing and the investment in research by the pharmaceutical industry. The just-completed analysis by the Tufts University Center for the Study of Drug Developme

Written byJack Jackson
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

BOSTON - An unpublished study that examines the cost of bringing a new drug to market has revived debate over whether data should be released to the public prior to peer review. The study, which cites a figure that is nearly twice as high as previous estimates, is already being used in ongoing discussions over federal policies on drug pricing and the investment in research by the pharmaceutical industry.

The just-completed analysis by the Tufts University Center for the Study of Drug Development reported that it takes 12 years and the equivalent of $231 million (in 1987 dollars) to bring a single new prescription drug to market. The cost cited is more than double that of 10 years ago, even after adjusting for inflation, and the length of time is two years longer than previously judged. About half of the total consists of "time costs," or money lost by forgoing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies